Patent Law Weblog
recent posts
- Why the Alice Test is Stupid, Part IV: The Usefulness Paradox
- Teva Capitulates to Federal Trade Commission Coercion
- USPTO Issues Memoranda on Subject Matter Eligibility
- USPTO Revokes Guidance on AI-Assisted Inventorship, But Rules Remain Basically the Same
- Why the Alice Test is Stupid, Part III: Eligible Independent Claims Can Have Ineligible Dependent Claims
about
Category: Biotech/Pharma Business
-
By Kevin E. Noonan – On Monday, September 12th, President Biden signed an Executive Order entitled "Advancing Biotechnology and Biomanufacturing Innovation for Sustainable, Safe and Secure American Bioeconomy." The Executive Order (in Section 1) set forth policy goals of taking a "whole-of-government" approach for using biotechnology in areas including "health, climate change, energy, food security, agriculture, supply…
-
By Kevin E. Noonan — Earlier this month, Eric Sagonowsky reviewed the top ten drugs in the U.S. (in terms of sales) losing patent exclusivity in an article published by Fierce Pharma. These drugs are Lucentis (Genentech/Roche), Bystolic (AbbVie/Allergan), Vascepa (Amarin), Nothera (Lundbeck), Narcan (Emergent Biosolutions), Brovana (Sunovion), Sutent (Pfizer), Saphris (AbbVie/Allergan), Amitiza (Mallinckrodt), and…
-
By Kevin E. Noonan — The Association for Molecular Pathology released a survey last week regarding the state of reimbursement for medical diagnostic testing, according to GenomeWeb. It seems that the state is parlous, with reimbursement for "data analysis, test interpretation, and reporting requirements" being inadequate. This reflects a need for "qualified molecular laboratory professionals"…
-
By Kevin E. Noonan — As reported in John Carrol's EndPoint News early last month, GlobalData has published a list of the Top 20 Pharmaceutical Companies by market cap as of March 31, 2019. Notable advances include Takeda (up 142% based in part on its Shire acquisition, and jumping in the rankings from 23rd to…
-
By Kevin E. Noonan — Rising drug prices is an issue that everyone from the President to both Houses of Congress (Democrats and Republicans), Wall Street, and Main Street can agree must be alleviated, and perhaps the most expensive drugs are those that treat cancer. This reality is a combination of the severity of the…
-
By Kevin E. Noonan — FiercePharma today reported sales rankings for the top 15 pharmaceutical companies in 2018, in comparison to 2017 sales. As reported today, "the top 15 names are the same against prior year rankings, but the order has shifted." 2018 sales were up for all reported companies except Gilead, AstraZeneca, and Teva,…
-
By Donald Zuhn — Earlier this year, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its Pitchbook NVCA Venture Monitor report on venture funding for the first quarter of 2018, noting that venture funding is on pace to experience another record-breaking year in 2018. …
-
By Kevin E. Noonan — Increased drug costs have been a political and economic target for more than the past generation, being one of the motivations for the Hatch-Waxman Act in 1984. Drug costs were a big part of Ross Perot's campaign in 1992, Hillary Clinton's ill-fated healthcare plans when she was First Lady, and…
-
By Donald Zuhn — PricewaterhouseCoopers (PwC) and CB Insight recently released the results of its US MoneyTreeTM Report on U.S. venture funding for the third quarter of 2017. The report indicates that venture capitalists invested $19.0 billion in 1,207 deals in the third quarter, with the number of dollars and deals remaining steady after $18.9…
-
By Donald Zuhn — PricewaterhouseCoopers (PwC) and CB Insight recently released the results of its US MoneyTreeTM Report on U.S. venture funding for the first quarter of 2017. The report indicates that venture capitalists invested $13.9 billion in 1,104 deals in the first quarter, which constituted a 15% increase in dollars and a 2% decrease…
Patent Docs 